Chugai Pharmaceutical Co., Ltd. (CHGCF)
USD 43.95
(44.76%)
USD 43.95
(44.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 325.47 Billion JPY | -13.08% |
| 2022 | 374.42 Billion JPY | 23.58% |
| 2021 | 302.99 Billion JPY | 41.1% |
| 2020 | 214.73 Billion JPY | 36.29% |
| 2019 | 157.56 Billion JPY | 70.36% |
| 2018 | 92.48 Billion JPY | 27.2% |
| 2017 | 72.71 Billion JPY | 35.68% |
| 2016 | 53.59 Billion JPY | -12.32% |
| 2015 | 61.12 Billion JPY | 19.9% |
| 2014 | 50.98 Billion JPY | 0.17% |
| 2013 | 50.89 Billion JPY | 5.58% |
| 2012 | 48.2 Billion JPY | 36.81% |
| 2011 | 35.23 Billion JPY | -14.96% |
| 2010 | 41.43 Billion JPY | -26.84% |
| 2009 | 56.63 Billion JPY | 44.24% |
| 2008 | 39.26 Billion JPY | -1.98% |
| 2007 | 40.06 Billion JPY | 4.28% |
| 2006 | 38.41 Billion JPY | -28.37% |
| 2005 | 53.63 Billion JPY | 57.2% |
| 2004 | 34.11 Billion JPY | 19.94% |
| 2003 | 28.44 Billion JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 74.4 Billion JPY | -18.43% |
| 2024 Q2 | 111.86 Billion JPY | 50.35% |
| 2023 Q3 | 77.57 Billion JPY | -6.76% |
| 2023 Q4 | 91.2 Billion JPY | 17.57% |
| 2023 Q1 | 73.5 Billion JPY | -28.28% |
| 2023 FY | 325.47 Billion JPY | -13.08% |
| 2023 Q2 | 83.19 Billion JPY | 13.19% |
| 2022 Q4 | 102.47 Billion JPY | 51.16% |
| 2022 Q2 | 72.37 Billion JPY | -45.07% |
| 2022 Q1 | 131.77 Billion JPY | 33.32% |
| 2022 FY | 374.42 Billion JPY | 23.58% |
| 2022 Q3 | 67.79 Billion JPY | -6.33% |
| 2021 Q2 | 70.72 Billion JPY | 49.18% |
| 2021 Q1 | 47.41 Billion JPY | -9.36% |
| 2021 FY | 302.99 Billion JPY | 41.1% |
| 2021 Q4 | 98.84 Billion JPY | 14.91% |
| 2021 Q3 | 86.01 Billion JPY | 21.62% |
| 2020 Q1 | 51.53 Billion JPY | 28.3% |
| 2020 Q3 | 60.13 Billion JPY | 18.47% |
| 2020 FY | 214.73 Billion JPY | 36.29% |
| 2020 Q4 | 52.3 Billion JPY | -13.01% |
| 2020 Q2 | 50.75 Billion JPY | -1.5% |
| 2019 Q3 | 48.14 Billion JPY | 40.66% |
| 2019 Q2 | 34.22 Billion JPY | -2.3% |
| 2019 FY | 157.56 Billion JPY | 70.36% |
| 2019 Q1 | 35.03 Billion JPY | 58.17% |
| 2019 Q4 | 40.16 Billion JPY | -16.57% |
| 2018 Q3 | 21.66 Billion JPY | 4.25% |
| 2018 Q4 | 22.14 Billion JPY | 2.22% |
| 2018 Q2 | 20.78 Billion JPY | -25.47% |
| 2018 Q1 | 27.88 Billion JPY | 79.73% |
| 2018 FY | 92.48 Billion JPY | 27.2% |
| 2017 Q4 | 15.51 Billion JPY | -26.45% |
| 2017 Q2 | 17.59 Billion JPY | -4.87% |
| 2017 Q1 | 18.5 Billion JPY | 76.06% |
| 2017 FY | 72.71 Billion JPY | 35.68% |
| 2017 Q3 | 21.09 Billion JPY | 19.88% |
| 2016 FY | 53.59 Billion JPY | -12.32% |
| 2016 Q3 | 11.53 Billion JPY | -32.34% |
| 2016 Q2 | 17.04 Billion JPY | 17.58% |
| 2016 Q1 | 14.5 Billion JPY | 7.58% |
| 2016 Q4 | 10.5 Billion JPY | -8.9% |
| 2015 FY | 61.12 Billion JPY | 19.9% |
| 2015 Q4 | 13.47 Billion JPY | -23.02% |
| 2015 Q3 | 17.5 Billion JPY | 12.55% |
| 2015 Q2 | 15.55 Billion JPY | 6.68% |
| 2015 Q1 | 14.58 Billion JPY | 29.62% |
| 2014 Q3 | 10.83 Billion JPY | 7.03% |
| 2014 Q4 | 11.25 Billion JPY | 3.85% |
| 2014 FY | 50.98 Billion JPY | 0.17% |
| 2014 Q1 | 18.77 Billion JPY | 47.48% |
| 2014 Q2 | 10.12 Billion JPY | -46.1% |
| 2013 Q4 | 12.73 Billion JPY | -5.11% |
| 2013 Q3 | 13.41 Billion JPY | -15.35% |
| 2013 FY | 50.89 Billion JPY | 5.58% |
| 2013 Q1 | 8.89 Billion JPY | -51.55% |
| 2013 Q2 | 15.85 Billion JPY | 78.15% |
| 2012 FY | 48.2 Billion JPY | 36.81% |
| 2012 Q1 | 10.7 Billion JPY | 32.13% |
| 2012 Q4 | 18.36 Billion JPY | 101.62% |
| 2012 Q3 | 9.1 Billion JPY | -16.6% |
| 2012 Q2 | 10.92 Billion JPY | 1.98% |
| 2011 Q4 | 8.1 Billion JPY | -19.28% |
| 2011 FY | 35.23 Billion JPY | -14.96% |
| 2011 Q3 | 10.04 Billion JPY | -17.0% |
| 2011 Q1 | 4.98 Billion JPY | -62.71% |
| 2011 Q2 | 12.09 Billion JPY | 142.49% |
| 2010 Q4 | 13.38 Billion JPY | 14.59% |
| 2010 Q2 | 8.52 Billion JPY | 8.56% |
| 2010 Q1 | 7.85 Billion JPY | -50.13% |
| 2010 FY | 41.43 Billion JPY | -26.84% |
| 2010 Q3 | 11.67 Billion JPY | 36.98% |
| 2009 Q1 | 13.76 Billion JPY | 0.0% |
| 2009 Q3 | 14.58 Billion JPY | 16.31% |
| 2009 Q4 | 15.74 Billion JPY | 7.97% |
| 2009 FY | 56.63 Billion JPY | 44.24% |
| 2009 Q2 | 12.53 Billion JPY | -8.93% |
| 2008 FY | 39.26 Billion JPY | -1.98% |
| 2007 FY | 40.06 Billion JPY | 4.28% |
| 2006 FY | 38.41 Billion JPY | -28.37% |
| 2005 FY | 53.63 Billion JPY | 57.2% |
| 2004 FY | 34.11 Billion JPY | 19.94% |
| 2003 FY | 28.44 Billion JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | -5365.525% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | -3955.726% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -39070.252% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 576034.315% |
| Novartis AG | 14.85 Billion USD | -2091.731% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -181014.058% |